Role of n-type voltage-dependent calcium channels in autoimmune optic neuritis

Ann Neurol. 2009 Jul;66(1):81-93. doi: 10.1002/ana.21668.

Abstract

Objective: The aim of this study was to investigate the role of voltage-dependent calcium channels (VDCCs) in axon degeneration during autoimmune optic neuritis.

Methods: Calcium ion (Ca(2+)) influx into the optic nerve (ON) through VDCCs was investigated in a rat model of optic neuritis using manganese-enhanced magnetic resonance imaging and in vivo calcium imaging. After having identified the most relevant channel subtype (N-type VDCCs), we correlated immunohistochemistry of channel expression with ON histopathology. In the confirmatory part of this work, we performed a treatment study using omega-conotoxin GVIA, an N-type specific blocker.

Results: We observed that pathological Ca(2+) influx into ONs during optic neuritis is mediated via N-type VDCCs. By analyzing the expression of VDCCs in the inflamed ONs, we detected an upregulation of alpha(1B), the pore-forming subunit of N-type VDCCs, in demyelinated axons. However, high expression levels were also found on macrophages/activated microglia, and lower levels were detected on astrocytes. The relevance of N-type VDCCs for inflammation-induced axonal degeneration and the severity of optic neuritis was corroborated by treatment with omega-conotoxin GVIA. This blocker led to decreased axon and myelin degeneration in the ONs together with a reduced number of macrophages/activated microglia. These protective effects were confirmed by analyzing the spinal cords of the same animals.

Interpretation: We conclude that N-type VDCCs play an important role in inflammation-induced axon degeneration via two mechanisms: First, they directly mediate toxic Ca(2+) influx into the axons; and second, they contribute to macrophage/microglia function, thereby promoting secondary axonal damage. Ann Neurol 2009;66:81-93.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2',3'-Cyclic-Nucleotide Phosphodiesterases / metabolism
  • Amlodipine / pharmacology
  • Amyloid beta-Protein Precursor / metabolism
  • Animals
  • Autoimmune Diseases / chemically induced
  • Autoimmune Diseases / metabolism*
  • Autoimmune Diseases / pathology
  • Calcium / metabolism
  • Calcium Channel Blockers / pharmacology
  • Calcium Channels, N-Type / metabolism*
  • Cytokines / metabolism
  • Disease Models, Animal
  • Drug Interactions
  • Ectodysplasins / metabolism
  • Egtazic Acid / analogs & derivatives
  • Excitatory Amino Acid Antagonists / pharmacology
  • Female
  • Glial Fibrillary Acidic Protein / metabolism
  • Magnetic Resonance Imaging / methods
  • Manganese / metabolism
  • Myelin Proteins
  • Myelin-Associated Glycoprotein
  • Myelin-Oligodendrocyte Glycoprotein
  • Neoplasm Proteins / metabolism
  • Optic Nerve / drug effects
  • Optic Nerve / metabolism
  • Optic Neuritis / chemically induced
  • Optic Neuritis / metabolism*
  • Optic Neuritis / pathology
  • Quinoxalines / pharmacology
  • RNA-Binding Proteins / metabolism
  • Rats
  • omega-Conotoxin GVIA / pharmacology

Substances

  • Amyloid beta-Protein Precursor
  • Calcium Channel Blockers
  • Calcium Channels, N-Type
  • Cytokines
  • Ectodysplasins
  • Excitatory Amino Acid Antagonists
  • Glial Fibrillary Acidic Protein
  • Mog protein, rat
  • Myelin Proteins
  • Myelin-Associated Glycoprotein
  • Myelin-Oligodendrocyte Glycoprotein
  • Neoplasm Proteins
  • Quinoxalines
  • RNA-Binding Proteins
  • small inducible cytokine subfamily E, member 1
  • 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
  • 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester
  • Amlodipine
  • Manganese
  • Egtazic Acid
  • omega-Conotoxin GVIA
  • 2',3'-Cyclic-Nucleotide Phosphodiesterases
  • Calcium